tbuckley/cabot-search huggingface dataset:
CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children — United States, 2023
Authors: Lakshmi Panagiotakopoulos, Amy L Sandul, Erin E. Conners, Monique A. Foster, Noele P. Nelson, Carolyn Wester, Elizabeth Barnett, Ravi Jhaveri, Gwen Lazenby, Christine Lee, Wael Mourad, Adam Ratner
Journal: MMWR Recommendations and Reports (2023)

The elimination of hepatitis C is a national priority (https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf). During 2010-2021, hepatitis C virus (HCV) acute and chronic infections (hereinafter referred to as HCV infections) increased in the United States, consequences of which include cirrhosis, liver cancer, and death. Rates of acute infections more than tripled among reproductive-aged persons during this time (from 0.8 to 2.5 per 100,000 population among persons aged 20-29 years and from 0.6 to 3.5 among persons aged 30-39 years). Because acute HCV infection can lead to chronic infection, this has resulted in increasing rates of HCV infections during pregnancy. Approximately 6%-7% of perinatally exposed (i.e., exposed during pregnancy or delivery) infants and children will acquire HCV infection. Curative direct-acting antiviral therapy is approved by the Food and Drug Administration for persons aged ≥3 years. However, many perinatally infected children are not tested or linked to care. In 2020, because of continued increases in HCV infections in the United States, CDC released universal screening recommendations for adults, which included recommendations for screening for pregnant persons during each pregnancy (Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults-United States, 2020. MMWR Recomm Rep 2020;69[No. RR-2]:1-17). This report introduces four new CDC recommendations: 1) HCV testing of all perinatally exposed infants with a nucleic acid test (NAT) for detection of HCV RNA at age 2-6 months; 2) consultation with a health care provider with expertise in pediatric hepatitis C management for all infants and children with detectable HCV RNA; 3) perinatally exposed infants and children with an undetectable HCV RNA result at or after age 2 months do not require further follow-up unless clinically warranted; and 4) a NAT for HCV RNA is recommended for perinatally exposed infants and children aged 7-17 months who previously have not been tested, and a hepatitis C virus antibody (anti-HCV) test followed by a reflex NAT for HCV RNA (when anti-HCV is reactive) is recommended for perinatally exposed children aged ≥18 months who previously have not been tested. Proper identification of perinatally infected children, referral to care, and curative treatment are critical to achieving the goal of hepatitis C elimination.
EP14.03-02 The Impact of Expanded Indication of Robot-Assisted Thoracic Surgery for Mediastinal Tumors
Authors: T. Kato, Y. Takada, H. Iwashimizu, Y. Imamura, S. Okado, Y. Nomata, H. Watanabe, O. Noritake, K. Nakanishi, Y. Kadomatsu, H. Ueno, S. Nakamura, T. Mizuno, T.F. Chen-Yoshikawa
Journal: Journal of Thoracic Oncology (2023)
OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC
Authors: M. Wermke, Y. Kuboki, E. Felip, O.B. Alese, D. Morgensztern, C. Sayehli, E. Arriola, M.F. Sanmamed, Z. Oum’ Hamed, E. Song, M. Studeny, V. Gambardella
Journal: Journal of Thoracic Oncology (2023)
EP14.01-08 Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin
Authors: J. Mengers, M. Haberecker, M.B. Kirschner, N. Bosbach, O. Lauk, I. Opitz, M. Meerang
Journal: Journal of Thoracic Oncology (2023)
WS08.08 Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes
Authors: E. Caballe, N. Hernandez-Pedro, M. Ramos-Ramirez, E. Romero-Nuñez, J. Lucio-Lozada, P. Barrios-Bernal, O. Arrieta
Journal: Journal of Thoracic Oncology (2023)
OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
Authors: S. Nakazawa, F. Pecci, B. Ricciuti, G. Harada, J.K. Lee, J.V. Alessi, A.P.C. Barrichello, V.R. Vaz, G. Lamberti, A. Di Federico, M.M. Gandhi, D. Gazgalis, W.W. Feng, J. Jiang, M. Chen, E. Lee, D. Haradon, A. Smokovich, E. Voligny, T. Nguyen, V. Goel, Z. Zimmerman, X. Wang, M. Bahcall, R. Heist, S. Iqbal, J. Che, A.B. Schrock, A. Drilon, P.A. Jänne, M.M. Awad
Journal: Journal of Thoracic Oncology (2023)
EP06.03-18 Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients
Authors: U. Malapelle, F. Pepe, F. Passiglia, P. Pisapia, M.L. Reale, D. Cortinovis, F. Fragetta, D. Galetta, E. Garbo, P. Graziano, F. Pagni, S. Pilotto, M. Tiseo, G. Troncone, S. Novello
Journal: Journal of Thoracic Oncology (2023)
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
Authors: P. Janne, D. Planchard, Y. Cheng, J.C.-H. Yang, N. Yanagitani, S.-W. Kim, S. Sugawara, Y. Yu, Y. Fan, S.L. Geater, K. Laktionov, C.K. Lee, N. Valdivieso, S. Ahmed, J.-M. Maurel, I. Andrasina, J. Goldman, D. Ghiorghiu, D. Kulkarni, X. Huang, K. Kobayashi
Journal: Journal of Thoracic Oncology (2023)
MA21.08 Usefulness of Bronchoscopic Cytology Pellets for Next Generation Sequencing
Authors: C. Mimura, M. Tachihara, R. Takamiya, S. Fujimoto, T. Fukui, J. Yamada, A. Yatani, N. Takata, M. Takayasu, H. Sato, K. Fukuda, D. Hazama, N. Katsurada, M. Yamamoto, K. Kobayashi
Journal: Journal of Thoracic Oncology (2023)
EP06.03-15 Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis
Authors: G. Soussi, A. Hercent, V. Gounant, A. Lupo, A. Cazes, J. Lamoril, A. Guyard, N. Théou-Anton
Journal: Journal of Thoracic Oncology (2023)
MA17.04 The IASLC Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma
Authors: A.S. Wolf, A. Rosenthal, D.J. Giroux, A.K. Nowak, A. Bille, M. de Perrot, H.L. Kindler, D. Rice, I. Opitz, V.W. Rusch, H.I. Pass
Journal: Journal of Thoracic Oncology (2023)
Smart pills and drug delivery devices enabling next generation oral dosage forms
Authors: Carmen Milián-Guimerá, Reece McCabe, Lasse Højlund Eklund Thamdrup, Mahdi Ghavami, Anja Boisen
Journal: Journal of Controlled Release (2023)

Oral dosage forms are the preferred solution for systemic treatment and prevention of disease conditions. However, traditional dosage forms face challenges regarding treatment adherence and delivery of biologics. Oral therapies that require frequent administrations face difficulties with patient compliance. In addition, only a few peptide- and protein-based drugs have been commercialized for oral administration so far, presenting a bioavailability that is generally low. Therefore, research and development on novel formulation strategies for oral drug delivery has bloomed massively in the last decade to overcome these challenges. On the one hand, approaches based on lumen-release of drugs such as 3D-printed capsules and prolonged gastric residence dosage forms have been explored to offer personalized medicine to the patient and reduce frequent dosing of small drug compounds that are currently in the market as powdered tablet or capsules. On the other hand, strategies based on mucus interfacing such as gastrointestinal patches, or even epithelium injections have been investigated in order to enhance the permeability of biologic macromolecules, which are mostly commercialized in the form of subcutaneous injections. Despite the fact that these methods are at an early development stage, promising results have been revealed in terms of personalized medicine and improved bioavailability. In this review, we offer a critical overview of novel ingestible millimeter-sized devices and technologies for oral drug delivery that are currently used in the clinic as well as those that could emerge on the market in a not too distant future.
OA13.06 The Epidemiology of Young Lung Cancer: Interim Analysis of Risk Factors and Genetic Mutations
Authors: M. Bittoni, A. Harper, A. Wu, N. Florez, J. King, R. Erwin, B. Addario, D. Carbone, B. Gitlitz, J. Nieva
Journal: Journal of Thoracic Oncology (2023)
OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630
Authors: A.S. Mansfield, J.V. Yin, P. Bradbury, D. Kwiatkowski, S. Patel, L. Bazhenova, P. Forde, Y. Lou, L. Villaruz, S. Arnold, M. Khalil, H. Kindler, M. Koczywas, J. Pacheco, C. Rolfo, B. Xia, E.R. Mikula, E. Sharon, J. Moscow, R. Hassan
Journal: Journal of Thoracic Oncology (2023)
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
Authors: Rahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, Vadim Koshkin, Rohit Bose, Jonathan Chou, Arpita Desai, Daniel Kwon, Samuel Kaushal, Lauren Trihy, Medini Rastogi, Robin Ippisch, Maya Aslam, Terence Friedlander, Felix Feng, David Oh, Alexander Cheung, Eric Small, Michael Evans, Lawrence Fong, Thomas A Hope
Journal: The Lancet Oncology (2023)
Safe and efficient oral allergy immunotherapy using one-pot-prepared mannan-coated allergen nanoparticles
Authors: Shunyi Li, Hiroki Toriumi, Daisuke Takahashi, Tomoko Kamasaki, Yoichiro Fujioka, Satoru Nagatoishi, Jinting Li, Yiwei Liu, Takanatsu Hosokawa, Kouhei Tsumoto, Yusuke Ohba, Yoshiki Katayama, Daisuke Murakami, Koji Hase, Takeshi Mori
Journal: Biomaterials (2023)
OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
Authors: B.C. Cho, M.C. Dols, R. Reyes Cabanillas, D. Vicente Baz, J. Fuentes Pradera, S. Grisanti, A.E. Gabayan, K.H. Lee, E.K. Cho, S. Mekan, F. Safavi, N. Fernando, M.J. Chisamore, M. Reck
Journal: Journal of Thoracic Oncology (2023)
EP14.01-11 Three-port Robot-assisted Thoracoscopic Surgery for Mediastinal Tumor with “Confronting View” at Our Hospital
Authors: Y. Hamada, S. Fujimori, S. Suzuki, T. Karasaki, S. Kikunaga, K. Ito, R. Ohtsuka, S. Mihara
Journal: Journal of Thoracic Oncology (2023)
OA04.03 Australian Registry and Biobank of Thoracic Cancers (AURORA) - A Multi-Site Research Platform and Longitudinal Cohort Study
Authors: J. Rogers, M. Itchins, S. Harden, G. Wright, A. Nagrial, S. Kao, S. Bowyer, I. Da Silva, S. Parakh, L. Warburton, B. Hughes, T. Clay, R. Tay, A. Mersiades, P. Blinman, S. Arulananda, A. Saqib, A. Officer, N. Pavlakis, B. Solomon, M. Alexander
Journal: Journal of Thoracic Oncology (2023)
OA03.05 A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK+ Non-small Cell Lung Cancer (NSCLC)
Authors: Y. Shi, J. Chen, R. Yang, H. Wu, Z. Wang, W. Yang, J. Cui, Y. Zhang, C. Liu, Y. Cheng, Y. Liu, J. Shan, D. Wang, L. Yang, C. Hu, J. Zhao, R. Cao, B. Tan, K. Xu, M. Si, H. Li, R. Mao, L. Li, X. Kang
Journal: Journal of Thoracic Oncology (2023)
EP13.07-05 RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer
Authors: Y. Yuan, G. Li, G. Han, F. Lin, R. Clift, D. Kim, E. Bischoff, K. Song, S. Moran
Journal: Journal of Thoracic Oncology (2023)
Influence of a Capsular Tension Ring on Capsular Bag Behavior of a Plate Haptic Intraocular Lens
Authors: Daniel Schartmüller, Veronika Röggla, Luca Schwarzenbacher, Elias Laurin Meyer, Claudette Abela-Formanek, Christina Leydolt, Rupert Menapace
Journal: Ophthalmology (2023)

To evaluate the influence of a capsular tension ring (CTR) on rotational stability, decentration, tilt, and axial stability of an 11.0-mm plate haptic intraocular lens (IOL).
OA08.04 Exploring Survivorship Care Needs for Low-Income Older Adults with Lung Cancer in a Safety-Net Setting: A Qualitative Study
Authors: A.I. Velazquez, E. Trejo, C. Hurtado, B.H.-F. Lau, N. Dixit, N. Florez, C. Kaplan
Journal: Journal of Thoracic Oncology (2023)
Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer
Authors: Wen Li, Jiali Huang, Chen Shen, Weiye Jiang, Xi Yang, Jingxuan Huang, Yueqing Gu, Zhiyu Li, Yi Ma, Jinlei Bian
Journal: Acta Pharmaceutica Sinica B (2023)

Recent progress in targeted metabolic therapy of cancer has been limited by the considerable toxicity associated with such drugs. To address this challenge, we developed a smart theranostic prodrug system that combines a fluorophore and an anticancer drug, specifically 6-diazo-5-oxo-l-norleucine (DON), using a thioketal linkage (TK). This system enables imaging, chemotherapy, photodynamic therapy, and on-demand drug release upon radiation exposure. The optimized prodrug, DON-TK-BM3, incorporating cyanine dyes as the fluorophore, displayed potent reactive oxygen species release and efficient tumor cell killing. Unlike the parent drug DON, DON-TK-BM3 exhibited no toxicity toward normal cells. Moreover, DON-TK-BM3 demonstrated high tumor accumulation and reduced side effects, including gastrointestinal toxicity, in mice. This study provides a practical strategy for designing prodrugs of metabolic inhibitors with significant toxicity stemming from their lack of tissue selectivity.
EP12.01-69 Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia
Authors: D.A.R. Amelia, C. Irawan, W. Rajabto, A. Kurniawan, C. Sari, M.A. Nasution, D. Djatnika, D. Priantono, F. Ariyanti, B.A. Wisman, N.P. Purlikasari, F. Dharmaraja, C. Nathalia
Journal: Journal of Thoracic Oncology (2023)
EP06.03-05 EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy
Authors: J. Park, J.-Y. Song, M. Sung, M.J. Kwon, C.R. Kim, Y.K. Shin, Y.-L. Choi
Journal: Journal of Thoracic Oncology (2023)
OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)
Authors: S. Peters, D.C. Christoph, J.K. Field, R. Fietkau, A.R. Filippi, M. Garassino, P. Garrido, F. McDonald, F. Mornex, B. Markman, B.J. Solomon, S. Anand, P. Chander, Y. Qiao, N. Girard
Journal: Journal of Thoracic Oncology (2023)
MA18.08 A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis
Authors: Y. Agemi, S. Ikeda, T. Ogura, T. Tokito, H. Kenmotsu, K. Ito, K. Isomoto, Y. Takiguchi, T. Kato, Y. Yoneshima, T. Yokoyama, T. Harada, T. Honda, N. Kobayashi, T. Iwasawa, T. Misumi, H. Okamoto
Journal: Journal of Thoracic Oncology (2023)
OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04
Authors: K.P. Papadopoulos, D. Bruno, S. Kitazono, S. Murakami, M. Gutierrez, K. Wakuda, A. Spira, K. Cuppens, S. Lovick, A. Hepner, G. Mak, S.N. Waqar
Journal: Journal of Thoracic Oncology (2023)
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
Authors: Philipp Karschnia, Marion Smits, Guido Reifenberger, Emilie Le Rhun, Benjamin M Ellingson, Norbert Galldiks, Michelle M Kim, Jason T Huse, Oliver Schnell, Patrick N Harter, Malte Mohme, Kenneth Aldape, Joachim M. Baehring, Lorenzo Bello, Daniel J. Brat, Daniel P. Cahill, Caroline Chung, Howard Colman, Jorg Dietrich, Katharine Drummond, Yoshua Esquenazi, Elizabeth R. Gerstner, Julia Furtner, Valentina Garibotto, Timothy J. Kaufmann, Takashi Komori, Rupesh Kotecha, Linda M. Liau, Janine M. Lupo, Giuseppe Minniti, Yoshitaka Narita, Maximilian Niyazi, Arie Perry, Matthias Preusser, Roberta Rudà, Nader Sanai, Nils-Ole Schmidt, Joachim P. Steinbach, Stefanie C. Thust, Nelleke Tolboom, Anouk van der Hoorn, Thijs van der Vaart, Antoine Verger, Einar Osland Vik-Mo, Colin Watts, Manfred Westphal, Pieter Wesseling, Jacob S. Young, Louisa von Baumgarten, Nathalie L Albert, Raymond Y Huang, Minesh P Mehta, Martin van den Bent, Michael Weller, Michael A Vogelbaum, Susan M Chang, Mitchel S Berger, Joerg-Christian Tonn
Journal: The Lancet Oncology (2023)
EP06.03-07 Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience
Authors: M. Anagnostakis, E. Panagiotou, A. Karachaliou, V. Kolintzikis, I. Tsamis, I.A. Vathiotis, N.K. Syrigos, V. Nikolaidou, A. Papafili, E. Kotteas
Journal: Journal of Thoracic Oncology (2023)
OA08.06 Development of a Lung Cancer Rehabilitation Core Outcome Set: An International Delphi Study (UNITE)
Authors: L. Edbrooke, C.L. Granger, J.J. Francis, T. John, N. Kaadan, E. Halloran, T. Davies, B. Connolly, L. Denehy
Journal: Journal of Thoracic Oncology (2023)
EP12.01-53 The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma
Authors: S.H. Kwak, E.H. Lee, H.R. Gwon, S.H. Yong, C.Y. Kim, S.H. Lee, Y.S. Chang, E.Y. Kim
Journal: Journal of Thoracic Oncology (2023)
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Authors: H.A. Yu, Y. Goto, H. Hayashi, E. Felip, J.C.-H. Yang, M. Reck, K. Yoh, S.-H. Lee, L. Paz-Ares, B. Besse, P. Bironzo, D.-W. Kim, M.L. Johnson, Y.-L. Wu, M. Vigliotti, Q. Dong, P.-D. Fan, P. Shrestha, D.W. Sternberg, D. Sellami, P.A. Jänne
Journal: Journal of Thoracic Oncology (2023)
MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study
Authors: P. Wheatley-Price, V. Navani, A. Pabani, B. Routy, S. Snow, M.-H. Denault, Y. Kim, I. Syed, N. Devost, D. Hui, P. Arora, R. Velummailum, A. Springford, C. McKibbon, C. Ho
Journal: Journal of Thoracic Oncology (2023)
OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
Authors: Y. Cheng, Y. Fan, Y. Zhao, D. Huang, X. Li, P. Zhang, M. Kang, N. Yang, D. Zhong, Z. Wang, Y. Yu, Y. Zhang, J. Zhao, T. Qin, C. Chen, S. Leaw, W. Zheng, Y. Song
Journal: Journal of Thoracic Oncology (2023)
Selective induction of Rab9-dependent alternative mitophagy using a synthetic derivative of isoquinoline alleviates mitochondrial dysfunction and cognitive deficits in Alzheimer's disease models
Authors: Jee-Hyun Um, Dong Jin Shin, Se Myeong Choi, Alen Benhur Pravin Nathan, Young Yeon Kim, Da Ye Lee, Dae Jin Jeong, Dong Hyun Kim, Kyung Hwa Kim, Young Hye Kim, Jihoon Nah, Jeong-hee Jeong, Eunhee Yoo, Hwa Kyoung Shin, Hwan Tae Park, Jihoon Jo, Jong Hyun Cho, Jeanho Yun
Journal: Theranostics (2023)

Promotion of mitophagy is considered a promising strategy for the treatment of neurodegenerative diseases including Alzheimer's disease (AD). The development of mitophagy-specific inducers with low toxicity and defined molecular mechanisms is essential for the clinical application of mitophagy-based therapy. The aim of this study was to investigate the potential of a novel small-molecule mitophagy inducer, ALT001, as a treatment for AD.
Long non-coding RNA DANCR stabilizes HIF-1α and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma: Erratum
Authors: Xin Wen, Xu Liu, Yan-Ping Mao, Xiao-Jing Yang, Ya-Qin Wang, Pan-Pan Zhang, Yuan Lei, Xiao-Hong Hong, Qing-Mei He, Jun Ma, Na Liu, Ying-Qin Li
Journal: Theranostics (2023)

[This corrects the article DOI: 10.7150/thno.28538.].
Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination
Authors: Jennifer E. Munt, Sandra Henein, Cameron Adams, Ellen Young, Yixuan J. Hou, Helen Conrad, Deanna Zhu, Stephanie Dong, Nurgun Kose, Boyd Yount, Rita M. Meganck, Long Ping V. Tse, Guillermina Kuan, Angel Balmaseda, Michael J. Ricciardi, David I. Watkins, James E. Crowe, Eva Harris, Aravinda M. DeSilva, Ralph S. Baric
Journal: Cell Host & Microbe (2023)
Evidence of shared genetic factors in the etiology of gastrointestinal disorders and endometriosis and clinical implications for disease management
Authors: Fei Yang, Yeda Wu, Richard Hockey, Jenny Doust, Gita D. Mishra, Grant W. Montgomery, Sally Mortlock
Journal: Cell Reports Medicine (2023)

In clinical practice, the co-existence of endometriosis and gastrointestinal symptoms is often observed. Using large-scale datasets, we report a genetic correlation between endometriosis and irritable bowel syndrome (IBS), peptic ulcer disease (PUD), gastro-esophageal reflux disease (GORD), and a combined GORD/PUD medicated (GPM) phenotype. Mendelian randomization analyses support a causal relationship between genetic predisposition to endometriosis and IBS and GPM. Identification of shared risk loci highlights biological pathways that may contribute to the pathogenesis of both diseases, including estrogen regulation and inflammation, and potential therapeutic drug targets (CCKBR; PDE4B). Higher use of IBS, GORD, and PUD medications in women with endometriosis and higher use of hormone therapies in women with IBS, GORD, and PUD, support the co-occurrence of these conditions and highlight the potential for drug repositioning and drug contraindications. Our results provide evidence of shared disease etiology and have important clinical implications for diagnostic and treatment decisions for both diseases.
Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins
Authors: Daniel J. McGrail, Yang Li, Roger S. Smith, Bin Feng, Hui Dai, Limei Hu, Briana Dennehey, Sharad Awasthi, Marc L. Mendillo, Anil K. Sood, Gordon B. Mills, Shiaw-Yih Lin, S. Stephen Yi, Nidhi Sahni
Journal: Cell Reports Medicine (2023)

Defects in homologous recombination DNA repair (HRD) both predispose to cancer development and produce therapeutic vulnerabilities, making it critical to define the spectrum of genetic events that cause HRD. However, we found that mutations in BRCA1/2 and other canonical HR genes only identified 10%–20% of tumors that display genomic evidence of HRD. Using a networks-based approach, we discovered that over half of putative genes causing HRD originated outside of canonical DNA damage response genes, with a particular enrichment for RNA-binding protein (RBP)-encoding genes. These putative drivers of HRD were experimentally validated, cross-validated in an independent cohort, and enriched in cancer-associated genome-wide association study loci. Mechanistic studies indicate that some RBPs are recruited to sites of DNA damage to facilitate repair, whereas others control the expression of canonical HR genes. Overall, this study greatly expands the repertoire of known drivers of HRD, with implications for basic biology, genetic screening, and therapy stratification.
Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach
Authors: Edward Lambert, Emmanuel Chartier-Kastler, Christophe Vaessen, Aurélien Beaugerie, Juliette Cotte, Morgan Roupret, Pierre Mozer, Jérôme Parra, Thomas Seisen, Louis Lenfant
Journal: European Urology (2023)
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers
Authors: Subir Biswas, Gunjan Mandal, Carmen M Anadon, Ricardo A Chaurio, Luis U Lopez-Bailon, Mate Z Nagy, Jessica A Mine, Kay Hänggi, Kimberly B Sprenger, Patrick Innamarato, Carly M Harro, John J Powers, Joseph Johnson, Bin Fang, Mostafa Eysha, Xiaolin Nan, Roger Li, Bradford A Perez, Tyler J Curiel, Xiaoqing Yu, Paulo C Rodriguez, Jose R Conejo-Garcia
Journal: Immunity (2023)

Dimeric IgA (dIgA) can move through cells via the IgA/IgM polymeric immunoglobulin receptor (PIGR), which is expressed mainly on mucosal epithelia. Here, we studied the ability of dIgA to target commonly mutated cytoplasmic oncodrivers. Mutation-specific dIgA, but not IgG, neutralized KRAS